Effective intracellular delivery of oligonucleotides in order to make sense of antisense

Journal of Controlled Release

Volumn 97, Issue 2, 2004, Pages 189-209

  Shi, Fuxin ^a   Hoekstra, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antisense design; Delivery vehicle; Oligonucleotides

Indexed keywords

CELLS; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; RNA;

ANTISENSE DESIGN; ANTISENSE OLIGONUCLEOTIDES (ODN); MEDICAL THERAPEUTICS;

GENES;

COMPLEMENTARY DNA; DRUG CARRIER; MESSENGER RNA; OLIGONUCLEOTIDE; RECOMBINANT DNA;

BIOACCUMULATION; CELL FRACTIONATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; CORRELATION ANALYSIS; CYTOTOXICITY; DNA LIBRARY; DNA MICROARRAY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULARY; DRUG MECHANISM; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; ENDOSOME; EXTRACELLULAR MATRIX; GENE SEQUENCE; HUMAN; KIDNEY NECROSIS; KINETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEQUENTIAL ANALYSIS; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA;

ANIMALS; CELL MEMBRANE; ENDOSOMES; HUMANS; NUCLEAR ENVELOPE; OLIGONUCLEOTIDES, ANTISENSE; RETICULOENDOTHELIAL SYSTEM;

EID: 2942585676     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.03.016     Document Type: Review

References (153)

1. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U. S. A. 75:1978;280-284
2. Vanhee-Brossollet C., Vaquero C. Do natural antisense transcripts make sense in eukaryotes? Gene. 211:1998;1-9
3. Lehner B., Williams G., Campbell R.D., Sanderson C.M. Antisense transcripts in the human genome. Trends Genet. 18:2002;63-65
4. Dias N., Dheur S., Nielsen P.E., Gryaznov S., Van-Aerschot A., Herdewijn P., Helene C., Saison-Behmoaras T.E. Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J. Mol. Biol. 294:1999;403-416
5. Sazani P., Gemignani F., Kang S.H., Maier M.A., Manoharan M., Persmark M., Bortner D., Kole R. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20:2002;1228-1233
6. De-Backer M.D., Nelissen B., Logghe M., Viaene J., Loonen I., Vandoninck S., de-Hoogt R., Dewaele S., Simons F.A., Verhasselt P., Vanhoof G., Contreras R., Luyten W.H. An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans. Nat. Biotechnol. 19:2001;235-241
7. Dean N.M. Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr. Opin. Biotechnol. 12:2001;622-625
8. Huber M., Mundlein A., Dornstauder E., Schneeberger C., Tempfer C.B., Mueller M.W., Schmidt W.M. Accessing single nucleotide polymorphisms in genomic DNA by direct multiplex polymerase chain reaction amplification on oligonucleotide microarrays. Anal. Biochem. 303:2002;25-33
9. Wagner R.W., Flanagan W.M. Antisense technology and prospects for therapy of viral infections and cancer. Mol. Med. Today. 3:1997;31-38
10. Holmlund J.T., Monia B.P., Kwoh T.J., Dorr F.A. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Curr. Opin. Molec. Ther. 1:1999;372-385
11. Hjelstuen O.K., Tonnesen H.H., Bremer P.O., Verbruggen A.M. Hybridization of a 99Tcm-labelled oligodeoxynucleotide to CAPL RNA. Nucl. Med. Biol. 25:1998;651-657
12. Shi N., Boado R.J., Pardridge W.M. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U. S. A. 97:2000;14709-14714
13. Lee H.J., Boado R.J., Braasch D.A., Corey D.R., Pardridge W.M. Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. J. Nucl. Med. 43:2002;948-956
14. Storey A., Oates D., Banks L., Crawford L., Crook T. Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res. 19:1991;4109-4114
15. Wang W., Chen H.J., Schwartz A., Cannon P.J., Stein C.A., Rabbani L.E. Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 98:1996;443-450
16. Anselmet A., Mayat E., Wietek S., Layer P.G., Payrastre B., Massoulie J. Non-antisense cellular responses to oligonucleotides. FEBS Lett. 510:2002;175-180
17. Rockwell P., O'Connor W.J., King K., Goldstein N.I., Zhang L.M., Stein C.A. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U. S. A. 94:1997;6523-6528
18. Coulson J.M., Poyner D.R., Chantry A., Irwin W.J., Akhtar S. A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. Mol. Pharmacol. 50:1996;314-325
19. Papucci L., Schiavone N., Donnini M., Lapucci A., Luzi E., Tempestini A., Witort E., Capaccioli S. Phosphodiester oligonucleotides inhibit mitosis and trigger apoptosis by a non-antisense, p53-mediated mechanism. Antisense Nucleic Acid Drug Dev. 12:2002;21-31
20. Anonymous Advances in CMV management: fomivirsen (Vitravene) approved. PI. Perspective. 26:1998;7
21. Anonymous AIDS-treatment-news Fomivirsen approved for CMV retinitis: first antisense drug. AIDS Treat. News. 302:1998;7
22. Li K., Zhang J. ISIS-3521. Isis Pharmaceuticals. Curr. Opin. Investig. Drugs. 2:2001;1454-1461
23. Gewirtz A.T., Sitaraman S. Alicaforsen. Isis Pharmaceuticals. Curr. Opin. Investig. Drugs. 2:2001;1401-1406
24. Banerjee D. Genasense (Genta). Curr. Opin. Investig. Drugs. 2:2001;574-580
25. Arzumanov A., Walsh A.P., Rajwanshi V.K., Kumar R., Wengel J., Gait M.J. Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry. 40:2001;14645-14654
26. Dias N., Senamaud-Beaufort C., Forestier-El E., Auvin C., Helene C., Ester-Saison-Behmoaras T. RNA hairpin invasion and ribosome elongation arrest by mixed base PNA oligomer. J. Mol. Biol. 320:2002;489-501
27. Baker B.F., Lot S.S., Condon T.P., Cheng-Flournoy S., Lesnik E.A., Sasmor H.M., Bennett C.F. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. 272:1997;11994-20000
28. Kole R., Mercatante D. Crooke S.T. Antisense Technology: Principles, Strategies and Applications. 2001;517-539 Marcel Dekker, New York
29. Vickers T.A., Wyatt J.R., Burckin T., Bennett C.F., Freier S.M. Fully modified 2′ MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res. 29:2001;1293-1299
30. Boiziau C., Thuong N.T., Toulme J.J. Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 89:1992;768-772
31. Crooke S.T., Lemonidis K.M., Neilson L., Griffey R., Lesnik E.A., Monia B.P. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312:1995;599-608
32. Veal G.J., Agrawal S., Byrn R.A. Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro. Nucleic Acids Res. 26:1998;5670-5675
33. Furrer P., Billeci T.M., Donati A., Kojima C., Karwowski B., Sierzchala A., Stec W., James T.L. Structural effect of complete [Rp]-phosphorothioate and phosphorodithioate substitutions in the DNA strand of a model antisense inhibitor-target RNA complex. J. Mol. Biol. 285:1999;1609-1622
34. Wu H., MacLeod A.R., Lima W.F., Crooke S.T. Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J. Biol. Chem. 273:1998;2532-2542
35. Carroll S.S., Chen E., Viscount T., Geib J., Sardana M.K., Gehman J., Kuo L.C. Cleavage of oligoribonucleotides by the 2′, 5′-oligoadenylate- dependent ribonuclease L. J. Biol. Chem. 271:1996;4988-4992
36. Zamore P.D., Tuschl T., Sharp P.A., Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 101:2000;25-33
37. Bernstein E., Caudy A.A., Hammond S.M., Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 409:2001;363-366
38. Zamore P.D. Ancient pathways programmed by small RNAs. Science. 296:2002;1265-1269
39. Conrad C., Rauhut R. Ribonuclease III: new sense from nuisance. Int. J. Biochem. Cell Biol. 34:2002;116-129
40. Ecker D.J., Vickers T.A., Bruice T.W., Freier S.M., Jenison R.D., Manoharan M., Zounes M. Pseudo-half-knot formation with RNA. Science. 257:1992;958-961
41. Stull R.A., Taylor L.A., Szoka F.C. Jr. Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices. Nucleic Acids Res. 20:1992;3501-3508
42. Hamilton S.E., Pitts A.E., Katipally R.R., Jia X., Rutter J.P., Davies B.A., Shay J.W., Wright W.E., Corey D.R. Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry. 36:1997;11873-11880
43. Petryshyn R.A., Ferrenz A.G., Li J. Characterization and mapping of the double-stranded regions involved in activation of PKR within a cellular RNA from 3T3-F442A cells. Nucleic Acids Res. 25:1997;2672-2678
44. Lima W.F., Brown-Driver V., Fox M., Hanecak R., Bruice T.W. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. 272:1997;626-638
45. Milner N., Mir K.U., Southern E.M. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol. 15:1997;537-541
46. Eckardt S., Romby P., Sczakiel G. Implications of RNA structure on the annealing of a potent antisense RNA directed against the human immunodeficiency virus type 1. Biochemistry. 36:1997;12711-12721
47. Vickers T.A., Wyatt J.R., Freier S.M. Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Res. 28:2000;1340-1347
48. Zhang W., Chen S.J. RNA hairpin-folding kinetics. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1931-1936
49. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science. 244:1989;48-52
50. Chalk A.M., Sonnhammer E.L. Computational antisense oligo prediction with a neural network model. Bioinformatics. 18:2002;1567-1575
51. Butler B.-A. Sequence analysis using GCG. Methods Biochem. Anal. 39:1998;74-97
52. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:2003;3406-3415
53. Wilson G.M., Sutphen K., Moutafis M., Sinha S., Brewer G. Structural remodeling of an A+ U-rich RNA element by cation or AUF1 binding. J. Biol. Chem. 276:2001;38400-38409
54. Raghunathan P.L., Guthrie C. A spliceosomal recycling factor that reanneals U4 and U6 small nuclear ribonucleoprotein particles. Science. 279:1998;857-860
55. Peyman A., Helsberg M., Kretzschmar G., Mag M., Grabley S., Uhlmann E. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol. Chem. Hoppe-Seyler. 376:1995;195-198
56. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:1996;668-675
57. Ding Y., Lawrence C.E. Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond. Nucleic Acids Res. 29:2001;1034-1046
58. Patzel V., Sczakiel G. Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nat. Biotechnol. 16:1998;64-68
59. Sohail M., Hochegger H., Klotzbucher A., Guellec R.L., Hunt T., Southern E.M. Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo. Nucleic Acids Res. 29:2001;2041-2051
60. Ho S.P., Britton D.H., Stone B.A., Behrens D.L., Leffet L.M., Hobbs F.W., Miller J.A., Trainor G.L. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24:1996;1901-1907
61. Matveeva O., Felden B., Audlin S., Gesteland R.F., Atkins J.F. A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res. 25:1997;5010-5016
62. Ho S.P., Bao Y., Lesher T., Malhotra R., Ma L.Y., Fluharty S.J., Sakai R.R. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 16:1998;59-63
63. Eckstein F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 10:2000;117-121
64. Geary R.S., Yu R.Z., Levin A.A. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr. Opin. Investig. New Drugs. 2:2001;562-573
65. Brown D.A., Kang S.H., Gryaznov S.M., DeDionisio L., Heidenreich O., Sullivan S., Xu X., Nerenberg M.I. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269:1994;26801-26805
66. Stein C.A. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochim. Biophys. Acta. 1489:1999;45-52
67. Guvakova M.A., Yakubov L.A., Vlodavsky I., Tonkinson J.L., Stein C.A. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J. Biol. Chem. 270:1995;2620-2627
68. Fennewald S.M., Rando R.F. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. J. Biol. Chem. 270:1995;21718-21721
69. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta. 1489:1999;141-158
70. Giles R.V., Spiller D.G., Clark R.E., Tidd D.M. Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev. 9:1999;213-220
71. Schmajuk G., Sierakowska H., Kole R. Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J. Biol. Chem. 274:1999;21783-21789
72. Koppelhus U., Zachar V., Nielsen P.E., Liu X., Eugen-Olsen J., Ebbesen P. Efficient in vitro inhibition of HIV-1 gag reverse transcription by peptide nucleic acid (PNA) at minimal ratios of PNA/RNA. Nucleic Acids Res. 25:1997;2167-2173
73. Lee R., Kaushik N., Modak M.J., Vinayak R., Pandey V.N. Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription. Biochemistry. 37:1998;900-910
74. Lomakin A., Frank-Kamenetskii M.D. A theoretical analysis of specificity of nucleic acid interactions with oligonucleotides and peptide nucleic acids (PNAs). J. Mol. Biol. 276:1998;57-70
75. Pitts A.E., Corey D.R. Inhibition of human telomerase by 2′-O-methyl-RNA. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11549-11554
76. Boado R.J., Kang Y.S., Wu D., Pardridge W.M. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). Drug Metab. Dispos. 23:1995;1297-1300
77. Glover J.M., Leeds J.M., Mant T.G., Amin D., Kisner D.L., Zuckerman J.E., Geary R.S., Levin A.A., Shanahan W.R. Jr. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282:1997;1173-1180
78. Leeds J.M., Henry S.P., Geary R., Burckin T., Levin A.A. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Antisense Nucleic Acid Drug Dev. 10:2000;435-441
79. McMahon B.M., Mays D., Lipsky J., Stewart J.A., Fauq A., Richelson E. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 12:2002;65-70
80. Wahlestedt C., Salmi P., Good L., Kela J., Johnsson T., Hokfelt T., Broberger C., Porreca F., Lai J., Ren K., Ossipov M., Koshkin A., Jakobsen N., Skouv J., Oerum H., Jacobsen M.H., Wengel J. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. U. S. A. 97:2000;5633-5638
81. Kurreck J., Wyszko E., Gillen C., Erdmann V.A. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30:2002;1911-1918
82. Fluiter K., ten-Asbroek A.L., de-Wissel M.B., Jakobs M.E., Wissenbach M., Olsson H., Olsen O., Oerum H., Baas F. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res. 31:2003;953-962
83. Brown-Driver V., Eto T., Lesnik E., Anderson K.P., Hanecak R.C. Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 9:1999;145-154
84. Teplova M., Minasov G., Tereshko V., Inamati G.B., Cook P.D., Manoharan M., Egli M. Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 6:1999;535-539
85. Geary R.S., Watanabe T.A., Truong L., Freier S., Lesnik E.A., Sioufi N.B., Sasmor H., Manoharan M., Levin A.A. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296:2001;890-897
86. Geary R.S., Khatsenko O., Bunker K., Crooke R., Moore M., Burckin T., Truong L., Sasmor H., Levin A.A. Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296:2001;898-904
87. Elayadi A.N., Demieville A., Wancewicz E.V., Monia B.P., Corey D.R. Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res. 29:2001;1683-1689
88. Zellweger T., Miyake H., Cooper S., Chi K., Conklin B.S., Monia B.P., Gleave M.E. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 298:2001;934-940
89. Sazani P., Kang S.H., Maier M.A., Wei C., Dillman J., Summerton J., Manoharan M., Kole R. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29:2001;3965-3974
90. Sazani P., Gemignani F., Kang S.H., Maier M.A., Manoharan M., Persmark M., Bortner D., Kole R. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20:2002;1228-1233
91. Grunweller A., Wyszko E., Bieber B., Jahnel R., Erdmann V.A., Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31:2003;3185-3193
92. Li B., Hughes J.A., Phillips M.I. Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem. Int. 31:1997;393-403
93. Hanss B., Leal-Pinto E., Bruggeman L.A., Copeland T.D., Klotman P.E. Identification and characterization of a cell membrane nucleic acid channel. Proc. Natl. Acad. Sci. U. S. A. 95:1998;1921-1926
94. Hanss B., Leal-Pinto E., Teixeira A., Christian R.E., Shabanowitz J., Hunt D.F., Klotman P.E. Cytosolic malate dehydrogenase confers selectivity of the nucleic acid-conducting channel. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1707-1712
95. Leonetti J.P., Mechti N., Degols G., Gagnor C., Lebleu B. Intracellular distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 88:1991;2702-2706
96. Fisher T.L., Terhorst T., Cao X., Wagner R.W. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res. 21:1993;3857-3865
97. Giles R.V., Spiller D.G., Tidd D.M. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5:1995;23-31
98. Spiller D.G., Tidd D.M. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res. Dev. 5:1995;13-21
99. Beltinger C., Saragovi H.U., Smith R.M., LeSauteur L., Shah N., DeDionisio L., Christensen L., Raible A., Jarett L., Gewirtz A.M. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95:1995;1814-1823
100. Hawley P., Gibson I. Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev. 6:1996;185-195
101. Zuhorn I.S., Kalicharan R., Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J. Biol. Chem. 277:2002;18021-18028
102. de-Semir D., Petriz J., Avinyo A., Larriba S., Nunes V., Casals T., Estivill X., Aran J.M. Non-viral vector-mediated uptake, distribution, and stability of chimeraplasts in human airway epithelial cells. J. Gene Med. 4:2002;308-322
103. Godbey W.T., Wu K.K., Mikos A.G. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5177-5181
104. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U. S. A. 91:1994;664-668
105. Allinquant B., Hantraye P., Mailleux P., Moya K., Bouillot C., Prochiantz A. Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell Biol. 128:1995;919-927
106. Troy C.M., Derossi D., Prochiantz A., Greene L.A., Shelanski M.L. Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J. Neurosci. 16:1996;253-261
107. Citro G., Perrotti D., Cucco C., D'Agnano I., Sacchi A., Zupi G., Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U. S. A. 89:1992;7031-7035
108. Citro G., Szczylik C., Ginobbi P., Zupi G., Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer. 69:1994;463-467
109. Bonfils E., Depierreux C., Midoux P., Thuong N.T., Monsigny M., Roche A.C. Drug targeting: synthesis and endocytosis of oligonucleotide- neoglycoprotein conjugates. Nucleic Acids Res. 20:1992;4621-4629
110. Liang W.W., Shi X., Deshpande D., Malanga C.J., Rojanasakul Y. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim. Biophys. Acta. 1279:1996;227-234
111. Oberle V., Bakowsky U., Zuhorn I.S., Hoekstra D. Lipoplex formation under equilibrium conditions reveals a three-step mechanism. Biophys. J. 79:2000;1447-1454
112. Maurer N., Wong K.F., Stark H., Louie L., McIntosh D., Wong T., Scherrer P., Semple S.C., Cullis P.R. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys. J. 80:2001;2310-2326
113. Bennett C.F., Chiang M.Y., Chan H., Shoemaker J.E., Mirabelli C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1992;1023-1033
114. DeLong R.K., Yoo H., Alahari S.K., Fisher M., Short S.M., Kang S.H., Kole R., Janout V., Regan S.L., Juliano R.L. Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. Nucleic Acids Res. 27:1999;3334-3341
115. Shi F., Nomden A., Oberle V., Engberts J.B., Hoekstra D. Efficient cationic lipid-mediated delivery of antisense oligonucleotides into eukaryotic cells: down-regulation of the corticotropin-releasing factor receptor. Nucleic Acids Res. 29:2001;2079-2087
116. Radler J.O., Koltover I., Salditt T., Safinya C.R. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science. 275:1997;810-814
117. Koltover I., Salditt T., Radler J.O., Safinya C.R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science. 281:1998;78-81
118. Smisterova J., Wagenaar A., Stuart M.C., Polushkin E., ten-Brinke G., Hulst R., Engberts J.B., Hoekstra D. Molecular shape of the cationic lipid controls the structure of cationic lipid/dioleylphosphatidylethanolamine-DNA complexes and the efficiency of gene delivery. J. Biol. Chem. 276:2001;47615-47622
119. Xu Y., Szoka F.C. Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry. 35:1996;5616-5623
120. Zelphati O., Szoka F.C. Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11493-11498
121. Zuhorn I.S., Oberle V., Visser W.H., Engberts J.B., Bakowsky U., Polushkin E., Hoekstra D. Phase behavior of cationic amphiphiles and their mixtures with helper lipid influences lipoplex shape, DNA translocation, and transfection efficiency. Biophys. J. 83:2002;2096-2108
122. Radler J.O., Koltover I., Salditt T., Safinya C.R. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science. 275:1997;810-814
123. Koltover I., Salditt T., Safinya C.R. Phase diagram, stability, and overcharging of lamellar cationic lipid-DNA self-assembled complexes. Biophys. J. 77:1999;915-924
124. Shi F., Wasungu L., Nomden A., Stuart M.C., Polushkin E., Engberts J.B., Hoekstra D. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem. J. 366:2002;333-341
125. Holland J.W., Cullis P.R., Madden T.D. Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer-forming lipids. Biochemistry. 35:1996;2610-2617
126. Johnsson M., Edwards K. Phase behavior and aggregate structure in mixtures of dioleoylphosphatidylethanolamine and poly(ethylene glycol)-lipids. Biophys. J. 80:2001;313-323
127. Song L.Y., Ahkong Q.F., Rong Q., Wang Z., Ansell S., Hope M.J., Mui B. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim. Biophys. Acta. 1558:2002;1-13
128. Zelphati O., Uyechi L.S., Barron L.G., Szoka F.C. Jr. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim. Biophys. Acta. 1390:1998;119-133
129. Lukacs G.L., Haggie P., Seksek O., Lechardeur D., Freedman N., Verkman A.S. Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. 275:2000;1625-1629
130. Shi F., Visser W.H., de Jong N.M.J., Liem R.S.B., Ronken E., Hoekstra D. Antisense oligonucleotides reach mRNA targets via the RNA matrix; downregulation of the 5-HT1A receptor. Exp. Cell Res. 291:2003;313-325
131. Lorenz P., Baker B.F., Bennett C.F., Spector D.L. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol. Biol. Cell. 9:1998;1007-1023
132. Lorenz P., Misteli T., Baker B.F., Bennett C.F., Spector D.L. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 28:2000;582-592
133. Marcusson E.G., Bhat B., Manoharan M., Bennett C.F., Dean N.M. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26:1998;2016-2023
134. Brunner S., Furtbauer E., Sauer T., Kursa M., Wagner E. Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation. Molec. Ther. 5:2002;80-86
135. Shoeman R.L., Hartig R., Huang Y., Grub S., Traub P. Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior. Antisense Nucleic Acid Drug Dev. 7:1997;291-308
136. Hartig R., Shoeman R.L., Janetzko A., Grub S., Traub P. Active nuclear import of single-stranded oligonucleotides and their complexes with non-karyophilic macromolecules. Biol. Cell. 90:1998;407-426
137. Lorenz P., Baker B.F., Bennett C.F., Spector D.L. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol. Biol. Cell. 9:1998;1007-1023
138. Zupan J.R., Citovsky V., Zambryski P. Agrobacterium VirE2 protein mediates nuclear uptake of single-stranded DNA in plant cells. Proc. Natl. Acad. Sci. U. S. A. 93:1996;2392-2397
139. Hartig R., Huang Y., Janetzko A., Shoeman R., Grub S., Traub P. Binding of fluorescence- and gold-labeled oligodeoxyribonucleotides to cytoplasmic intermediate filaments in epithelial and fibroblast cells. Exp. Cell Res. 233:1997;169-186
140. Chauhan N.B. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain. Antisense Nucleic Acid Drug Dev. 12:2002;353-357
141. Graham M.J., Crooke S.T., Monteith D.K., Cooper S.R., Lemonidis K.M., Stecker K.K., Martin M.J., Crooke R.M. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286:1998;447-458
142. Pardridge W.M., Boado R.J., Kang Y.S. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:1995;5592-5596
143. Penichet M.L., Kang Y.S., Pardridge W.M., Morrison S.L., Shin S.U. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J. Immunol. 163:1999;4421-4426
144. Wheeler J.J., Palmer L., Ossanlou M., MacLachlan I., Graham R.W., Zhang Y.P., Hope M.J., Scherrer P., Cullis P.R. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 6:1999;271-281
145. Hu Q., Shew C.R., Bally M.B., Madden T.D. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim. Biophys. Acta. 1514:2001;1-13
146. Sarmiento U.M., Perez J.R., Becker J.M., Narayanan R. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4:1994;99-107
147. Agrawal S., Rustagi P.K., Shaw D.R. Novel enzymatic and immunological responses to oligonucleotides. Toxicol. Lett. 82-83:1995;431-434
148. Bitter-Suermann D., Burger R., Hadding U. Activation of the alternative pathway of complement: efficient fluid-phase amplification by blockade of the regulatory complement protein beta1H through sulfated polyanions. Eur. J. Immunol. 11:1981;291-295
149. Wallace T.L., Bazemore S.A., Kornbrust D.J., Cossum P.A. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278:1996;1306-1312
150. Henry S.P., Novotny W., Leeds J., Auletta C., Kornbrust D.J. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7:1997;503-510
151. Flaherty K.T., Stevenson J.P., O'Dwyer P.J. Antisense therapeutics: lessons from early clinical trials. Curr. Opin. Oncol. 13:2001;499-505
152. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:1998;806-811
153. Grishok A., Tabara H., Mello C.C. Genetic requirements for inheritance of RNAi in C. elegans. Science. 287:2000;2494-2497